Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Contact dermatitis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    48 result(s) found for: Contact dermatitis. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2019-001324-35 Sponsor Protocol Number: ZKSJ0119_AD-HERE Start Date*: 2019-12-09
    Sponsor Name:Friedrich-Schiller-University Jena
    Full Title: Randomized single-blind study on the adherence to treatment with topical methylprednisolone aceponate (Advantan®) in different vehicles (AD-HERE)
    Medical condition: Hand eczema
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003641 Atopic eczema LLT
    20.0 100000004858 10010803 Contact eczema LLT
    21.1 100000004858 10056540 Dermatitis irritant contact LLT
    20.0 100000004858 10078681 Chronic cumulative irritant contact eczema LLT
    20.0 100000004858 10010791 Contact dermatitis and other eczema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011931-11 Sponsor Protocol Number: H 552 000 - 0911 Start Date*: Information not available in EudraCT
    Sponsor Name:Almirall Hermal GmbH
    Full Title: Explorative, double-blind, randomized, controlled multi-center phase II study to evaluate the efficacy and safety of topically applied combinational product LAS41003 once daily versus corresponding...
    Medical condition: Patients aged 18 and older suffering from at least one clinically diagnosed superinfected or impetiginised eczema such as e.g. • superinfected or impetiginised atopic eczema • superinfected or impe...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10021773 Infected eczema LLT
    12.0 10014184 Eczema LLT
    12.0 10014188 Eczema allergic LLT
    12.0 10014191 Eczema atopic LLT
    12.0 10014199 Eczema infected LLT
    12.0 10014201 Eczema nummular LLT
    12.0 10051890 Eczema impetiginous LLT
    12.0 10000618 Actinic reticuloid-photosensitive eczema LLT
    12.0 10001712 Allergic eczema LLT
    12.0 10003641 Atopic eczema LLT
    12.0 10010803 Contact eczema LLT
    12.0 10014206 Eczematous dermatitis LLT
    12.0 10021773 Infected eczema LLT
    12.0 10049706 Eczematous dermatitis infected LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004791-12 Sponsor Protocol Number: TIONICKEL Start Date*: 2006-06-30
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: VALUTATION OF AN ORAL HYPOSENSITIZATION TREATMENT IN PATIENTS WITH ALLERGIC CONTACT DERMATITIS TO NICKEL SULPHATE
    Medical condition: Allergic contact dermatitis to nickel sulphate
    Disease: Version SOC Term Classification Code Term Level
    6.1 10012442 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004331-38 Sponsor Protocol Number: olux 01/08 Start Date*: 2008-08-28
    Sponsor Name:MIPHARM
    Full Title: Randomized study on the effectiveness, safety and acceptability 'of clobetasol propionate foam-cooled (OLUX) in comparison with cream aceponato methylprednisolone in the treatment of allergic conta...
    Medical condition: Patients suffering from mild to moderate DAC with interest of body surface area not exceeding 20%
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056265 Allergic contact dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003725-17 Sponsor Protocol Number: D2213C00001 Start Date*: 2015-04-15
    Sponsor Name:MedImmune
    Full Title: A Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Tralokinumab in Adult Subjects with Moderate-to-Severe Atopic Dermatitis
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-000168-18 Sponsor Protocol Number: Mekos 07 7P3.2 301 Start Date*: 2008-04-10
    Sponsor Name:Allerderm
    Full Title: Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Gold Sodium Thiosulfate, Hydrocortisone-17-butyrate, Methyldibromoglutaronitrile, Bacitracin, Parthenolide, Disperse Blue 106, and Bronopol
    Medical condition: Diagnosis of Allergic Contact Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010790 Contact dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002203-34 Sponsor Protocol Number: M16-813 Start Date*: 2021-04-28
    Sponsor Name:AbbVie Deutschland
    Full Title: A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult and Adolescent Subjects with Moderate to Severe Atopic Dermatitis
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-007130-19 Sponsor Protocol Number: Mekos 07 2P3.2 201 Start Date*: 2008-11-28
    Sponsor Name:Allerderm
    Full Title: Clinical Evaluation of TRUE TEST® Panel 3.2 Allergens: Bronopol and Disperse Blue 106 Dose Response Study
    Medical condition: Diagnosis of Allergic Contact Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056265 Allergic contact dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024279-14 Sponsor Protocol Number: 1403440 Start Date*: 2011-04-08
    Sponsor Name:Intendis GmbH
    Full Title: Double-blind, randomized, vehicle-controlled, multicenter, multinational, parallel-group study of the efficacy and safety of mapracorat ointment in concentrations of 0.01%, 0.03% and 0.1% over max....
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003639 Atopic dermatitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-005389-36 Sponsor Protocol Number: CT327-2005 Start Date*: 2013-05-22
    Sponsor Name:Creabilis Limited
    Full Title: A phase II randomised, double blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of CT327 topical ointment (0.05% and 0.5% w/w) compared to vehicle, in subjects with ...
    Medical condition: Atopic Dermatitis (eczema)
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004858 10003641 Atopic eczema LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004257-81 Sponsor Protocol Number: SP121PL201 Start Date*: 2012-12-10
    Sponsor Name:SmartPractice
    Full Title: Clinical Evaluation of Hydroxyisohexyl 3-cyclohexene carboxaldehyde (Lyral®) Dose Response Study
    Medical condition: Diagnosis of Allergic Contact Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004858 10056265 Allergic contact dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-017481-23 Sponsor Protocol Number: SPD09P1401 Start Date*: 2010-10-15
    Sponsor Name:SmartPractice
    Full Title: Clinical Evaluation of T.R.U.E. TEST® Neomycin Sulfate and Potassium Dichromate Allergens: Bioequivalence of Vehicle Formulations
    Medical condition: Diagnosis of Allergic Contact Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10056265 Allergic contact dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-004750-39 Sponsor Protocol Number: LEOSIC Start Date*: 2022-07-08
    Sponsor Name:Herlev Gentofte Hospital - Department of Dermatology and Allergy
    Full Title: The role of Interleukin-1B targeted therapy for patients suffering with allergic contact dermatitis: A randomized controlled trial with Anakinra vs. Placebo.
    Medical condition: Allergic contact dermatitis. Patients with nickel allergy to be specific
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10056265 Allergic contact dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-002967-23 Sponsor Protocol Number: M-17923-30 Start Date*: 2022-01-27
    Sponsor Name:Almirall, S.A.
    Full Title: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adult and Adolescent Patients ...
    Medical condition: atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed) PL (Completed) BE (Completed) IT (Completed) NL (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004767-77 Sponsor Protocol Number: IM018-005 Start Date*: 2021-10-27
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients with Moderate to Severe Atopic Dermatitis
    Medical condition: Moderate to Severe Atopic Dermatitis.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001625-79 Sponsor Protocol Number: AK002-018 Start Date*: 2022-11-21
    Sponsor Name:Allakos Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Lirentelimab in Adult Subjects with Moderate-to-Severe Atopic Dermatitis Inadequatel...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000629-30 Sponsor Protocol Number: 06022013 Start Date*: 2013-04-09
    Sponsor Name:Department of surgery, Herlev Hospital
    Full Title: The sun protective effect of melatonin: a randomized, placebo-controlled, double-blinded study on healthy volunteers.
    Medical condition: Erythema after sun exposure in healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004858 10045745 Unspecified dermatitis due to sun LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001142-10 Sponsor Protocol Number: MOR106-CL-201 Start Date*: 2018-04-26
    Sponsor Name:Galapagos N.V.
    Full Title: A Phase II, randomized, double-blind, placebo-controlled repeated-dose study to evaluate the efficacy, safety, tolerability, and PK/PD of intravenously administered MOR106 in adult subjects with mo...
    Medical condition: atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000610-26 Sponsor Protocol Number: MK-4117-202 Start Date*: 2017-02-09
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Multicenter, Open-Label Long-Term Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Eczema/Dermatitis and Dermal Pruritus.
    Medical condition: Eczema/dermatitis and the dermal pruritus (itchy skin disease)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10012431 Dermatitis PT
    19.1 10040785 - Skin and subcutaneous tissue disorders 10014184 Eczema PT
    19.1 10040785 - Skin and subcutaneous tissue disorders 10037090 Pruritus cutaneous LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-003899-12 Sponsor Protocol Number: 271-12-205 Start Date*: 2014-10-22
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: Protocol 271-12-205: A Phase 2 Multi-center, Randomized, Double-blind, Vehicle-controlled, Three-arm, Parallel Group Study to Assess the Safety, Tolerability, and Efficacy of Topical OPA-15406 Oint...
    Medical condition: Mild/Moderate Atopic Dermatitis (AD)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    17.1 10040785 - Skin and subcutaneous tissue disorders 10003639 Atopic dermatitis LLT
    17.1 10040785 - Skin and subcutaneous tissue disorders 10014982 Epidermal and dermal conditions HLGT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 11:28:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA